drugset / Trial / NCT06520553

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body

NCT06520553

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The main objectives of this trial are: * To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to healthy male subjects (test treatment, T). * To investigate the absolute bioavailability of BI 1569912 as single oral solution dose, using a single, concomitant intravenous micro-tracer administration of BI 1569912 (C-13) (reference treatment, R)

Timeline

Start
2024-08-26
Primary completion
2024-10-03
Completion
2024-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1569912 Unknown 100 ug Oral
Subject BI 1569912 Unknown 10 mg Oral

Indications

No indication recorded.